Edition:
United States

Biotest AG (BIOG.DE)

BIOG.DE on Xetra

19.83EUR
28 Mar 2017
Change (% chg)

€0.46 (+2.37%)
Prev Close
€19.37
Open
€19.59
Day's High
€19.90
Day's Low
€19.58
Volume
12,105
Avg. Vol
10,926
52-wk High
€20.28
52-wk Low
€15.44

Latest Key Developments (Source: Significant Developments)

Biotest: European Commission approves recombinant clotting factor VIII Vihuma
Wednesday, 1 Mar 2017 01:00am EST 

Biotest AG : Recombinant clotting factor VIII with the name Vihuma approved .Market launch in Germany end of April 2017.  Full Article

Biotest says proceedings against Biotest have been closed
Friday, 17 Feb 2017 07:30am EST 

Biotest Ag : Proceedings against Biotest have been closed . Since a provision for this amount has already been recognised in financial year 2016, payment has no effect on result in 2017 financial year . Besides tax payment already communicated on Nov. 4, 2016, Biotest has paid a corporate fine in amount of 1.0 million euros. Thereby proceedings against Biotest are closed. . Public prosecution has moreover ceased investigation proceedings against several employees of company .Proceedings against three managers of Biotest AG, including CFO, continue.  Full Article

Biotest posts 2016 EBIT in continued operations of 64.4 mln euros
Thursday, 16 Feb 2017 04:48am EST 

Biotest AG : Revenues of all business areas of Biotest Group reached 610.4 million euros ($648.98 million) in full year 2016 after 589.6 million euros in 2015 (+3.5 pct) . EBIT-Margin in continued operations increased from 7.0 pct in 2015 to 11.6 pct in 2016 . Biotest Group reports EBIT (earnings before interest and tax) in continued operations in amount of 64.4 million euros in full year 2016. This represents an increase of 72.7 pct compared with previous year .Compared to previous year revenues in continued operations increased by 3.5 pct to 553.1 million euros in 2016 (2015: 534.6 million euros).  Full Article

Biotest to sell US therapy business to ADMA Biologics Inc.
Monday, 23 Jan 2017 07:00am EST 

Biotest AG : Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc . As part of transaction, biotest will contribute 11.5 million euros ($12.34 million) in cash as well as a 14 million euros loan . EBIT of continued operations is expected to improve by approx. 30 million euros in fiscal year 2016 . In addition, Biotest will contribute up to 11.5 million euros towards a future capital increase of adma on equal terms as third party investors .Transaction is expected to close during first half of 2017.  Full Article

Biotest 9-mth revenues up at 455.6 mln euros
Thursday, 10 Nov 2016 03:02am EST 

Biotest AG : Guidance confirmed . EBIT amounted to 26.1 million euros ($28.53 million)in first nine months of 2016 compared to previous year's figure of -82.0 million euros . 9-month generated revenues of 455.6 million euros, after 417.9 million euros in same period of previous year . In first nine months of 2016, biotest group recorded a positive operating cash flow in amount of 46.9 million euros(same period of previous year: 34.2 million euros) despite non-recurring tax payments . 9-month earnings after taxes in amount of -1.7 million euros (same period of previous year: -88.0 million euros) .dgap-news: biotest ag: biotest increases revenues by 9%.  Full Article

Biotest: proceedings against Biotest are close to be completed
Friday, 4 Nov 2016 08:41am EDT 

Biotest AG : Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest - proceedings against Biotest are close to be completed . Compared to tax assessments served on Aug. 3, which has already been reported on by company, there is a decrease in tax and interest expenses of 6.9 million euros ($7.65 million) . Original total claim of tax office had been 21.4 million euros, tax and interest expenses now come to a total of 14.5 million euros Biotest accepts these altered tax assessments . In meantime, authorities discontinued investigations against several defendants from Biotest . According to information from authorities, discontinuations of further investigations will follow . Authorities still investigate against three of company's managers .Based on these developments, company assumes that no further significant negative effects for company are to be expected from Russian business.  Full Article

Biotest opens new plasma collection centre in Vermillion, USA
Wednesday, 28 Sep 2016 03:16am EDT 

Biotest AG :Biotest opens new plasma collection centre in Vermillion, South Dakota, USA.  Full Article

Biotest H1 result after tax swings to profit of EUR 7.7 mln
Thursday, 11 Aug 2016 04:01am EDT 

Biotest AG : H1 revenue rose 6.4 percent to 306.1 million euros ($341.18 million) . H1 EBIT increased considerably from 2.3 million euros to 18.2 million euros . H1 pretax profit 13.9 million euros . H1 profit after tax 7.7 million euros versus -2.2 million euros loss year ago .Board of management confirms guidance of an increase in sales in low single-digit percentage range and an EBIT in range of 33 million to 35 million euros for 2016.  Full Article

Biotest: altered tax assessments for 2005 - 2008
Wednesday, 3 Aug 2016 12:15pm EDT 

Biotest AG : Altered tax assessments for 2005 - 2008 . Tax Office Offenbach am Main served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for years 2005 until 2008 . Alterations are based on investigations by tax authorities and public prosecutor in connection with Russia business of Biotest AG . This leads to liabilities for tax and interest totalling to approx. 20 million euros ($22.34 million) . Company will have tax assessments evaluated by their tax consultants .According to our first appraisal this approach by financial authorities is conflicting with recently published decisions by Federal Fiscal Court on tax deduction of operating expenses.  Full Article

Biotest opens fifth plasma collection centre in Hungary
Friday, 29 Jul 2016 03:00am EDT 

Biotest AG :Opens fifth plasma collection centre in Hungary.  Full Article

More From Around the Web

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)